Incretin-based therapies such as DPP-4 inhibitors have demonstrated the ability to potentiate GABAergic, dopaminergic, serotonergic, and noradrenergic neurotransmission, which are crucial pathways for awakening drugs in both coma and prolonged DOC (see Introduction). This evidence concerns the gene GCG and type 2 diabetes mellitus.